194 related articles for article (PubMed ID: 38104968)
21. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
[TBL] [Abstract][Full Text] [Related]
23. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
24. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
25. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
Gallipoli P; Cook A; Rhodes S; Hopcroft L; Wheadon H; Whetton AD; Jørgensen HG; Bhatia R; Holyoake TL
Blood; 2014 Aug; 124(9):1492-501. PubMed ID: 24957147
[TBL] [Abstract][Full Text] [Related]
26. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
28. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
29. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
30. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
31. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
33. Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib.
Kondratyev M; Rudnev VR; Nikolsky KS; Stepanov AA; Petrovsky DV; Kulikova LI; Kopylov AT; Malsagova KA; Kaysheva AL
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142375
[TBL] [Abstract][Full Text] [Related]
34. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Nieborowska-Skorska M; Maifrede S; Dasgupta Y; Sullivan K; Flis S; Le BV; Solecka M; Belyaeva EA; Kubovcakova L; Nawrocki M; Kirschner M; Zhao H; Prchal JT; Piwocka K; Moliterno AR; Wasik M; Koschmieder S; Green TR; Skoda RC; Skorski T
Blood; 2017 Dec; 130(26):2848-2859. PubMed ID: 29042365
[TBL] [Abstract][Full Text] [Related]
37. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
38. A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).
Zhao L; Ma Y; Seemann J; Huang LJ
Biochem J; 2010 Jan; 426(1):91-8. PubMed ID: 19929856
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic resistance to JAK2 inhibition in myelofibrosis.
Kalota A; Jeschke GR; Carroll M; Hexner EO
Clin Cancer Res; 2013 Apr; 19(7):1729-39. PubMed ID: 23386690
[TBL] [Abstract][Full Text] [Related]
40. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2
Courdy C; Platteeuw L; Ducau C; De Araujo I; Boet E; Sahal A; Saland E; Edmond V; Tavitian S; Bertoli S; Cougoul P; Granat F; Poillet L; Marty C; Plo I; Sarry JE; Manenti S; Mansat-De Mas V; Joffre C
Blood Cancer J; 2023 Jul; 13(1):106. PubMed ID: 37423955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]